The Market Reports

Synopsis
The global market for Gene Therapy was estimated to be worth US$ 11480 million in 2024 and is forecast to a readjusted size of US$ 61870 million by 2031 with a CAGR of 27.6% during the forecast period 2025-2031.
Gene therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.
The Gene Therapy market is driven by the growing demand for innovative treatments for rare genetic disorders, cancers, and chronic diseases that lack effective conventional therapies. Advancements in gene editing technologies such as CRISPR/Cas9, improved viral and non-viral delivery vectors, and increasing knowledge of the human genome have made gene therapy a promising option in precision medicine. Regulatory agencies are also offering accelerated approval pathways for breakthrough gene therapies, encouraging investment and speeding up clinical development. In addition, rising public and private funding, along with successful commercialization of landmark therapies like Zolgensma and Luxturna, are fueling confidence and expansion in this market.
Despite its potential, the Gene Therapy market faces several critical challenges, including high development and treatment costs, complex manufacturing processes, and safety concerns. Producing gene therapies requires highly specialized facilities and stringent quality control, leading to limited scalability and high prices, which can exceed millions of dollars per patient. Furthermore, long-term safety data are still lacking, with concerns over immune responses, off-target effects, and durability of treatment outcomes. Regulatory, ethical, and reimbursement hurdles also pose significant barriers to broader adoption. Addressing these challenges is essential to ensure accessibility, affordability, and the long-term success of gene therapy as a mainstream medical solution.
Global Gene Therapy key players include Biogen, Novartis, Gilead Sciences, etc. Global top three manufacturers hold a share about 75%. North America is the largest market, with a share about 60%, followed by Europe and Asia-Pacific, both have a share about 35 percent. In terms of product, Non-viral Gene Therapy is the largest segment, with a share about 55%. And in terms of application, the largest application is Neurological Diseases, followed by Cancer.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Gene Therapy by region & country, by Type, and by Application.
The Gene Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy.
Market Segmentation
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Roche
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
CSL Behring
BioMarin Pharmaceutical
Segment by Type
Viral Gene Therapy
Non-Viral Gene Therapy
Segment by Application
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Gene Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index